Sponsor: SWOG
Sponsor Study ID: S1900K
Study Title: A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
CTO #: 104055
NCT Number: NCT06031688
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: The primary objective is to compare the response rate (confirmed or unconfirmed, complete or partial) between participants with MET exon 14 skipping positive NSCLC randomized to tepotinib with or without ramucirumab. To compare the frequency of all-grade treatment- related peripheral edema as defined by CTCAE between the arms. To evaluate the frequency and severity of toxicities within each arm. To compare progression-free survival between the arms. To compare overall survival between the arms. To estimate the duration of response (DoR) among responders within each arm